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A B S T R A C T   
Amyotrophic Lateral Sclerosis (ALS) is a devastating heterogeneous disease with still no convincing therapy. To 
identify the most strategically significant hallmarks for therapeutic intervention, we have performed a 
comprehensive transcriptomics analysis of dysregulated pathways, comparing datasets from ALS patients and 
healthy donors. We have identified crucial alterations in RNA metabolism, intracellular transport, vascular 
system, redox homeostasis, proteostasis and inflammatory responses. Interestingly, the transcription factor NRF2 
(nuclear factor (erythroid-derived 2)-like 2) has significant effects in modulating these pathways. NRF2 has been 
classically considered as the master regulator of the antioxidant cellular response, although it is currently 
considered as a key component of the transduction machinery to maintain coordinated control of protein quality, 
inflammation, and redox homeostasis. Herein, we will summarize the data from NRF2 activators in ALS pre- 
clinical models as well as those that are being studied in clinical trials. As we will discuss, NRF2 is a prom-
ising target to build a coordinated transcriptional response to motor neuron injury, highlighting its therapeutic 
potential to combat ALS.   
1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a devastating disease that in-
volves the progressive degeneration of motor neurons in the cerebral 
cortex, brain stem, and spinal cord [1]. Although ALS is perceived as a 
rare disease, it is the third most common neurodegenerative disease 
after Alzheimer’s (AD) and Parkinson’s (PD) [2], and has a lifetime risk 
of approximately 1 in 300. Death usually occurs within two to three 
years from diagnosis, often as a consequence of respiratory failure [1,3]. 
The pathological hallmarks of this disease and their correlation with 
clinical manifestations have been studied in detail. Thus, degeneration 
of upper motor neurons (MN) leads to spasticity in the limbs and bulbar 
musculature, overall clumsiness, markedly brisk reflexes, and pyramidal 
distribution weakness. Degeneration of lower MN neurons in brainstem 
motor nuclei and in the ventral horn of the spinal cord leads to muscle 
weakness, atrophy and fasciculations. In addition to the MN related 
symptoms, up to 50 % of cases also show evidence of mild cognitive 
impairment and approximately 5 % develop overt features of fronto-
temporal dementia (FTD) [4,5]. 
In spite of the good clinical knowledge of ALS pathogenesis, no 
relevant disease-modifying drug is currently available [6], turning this 
disease into a rapidly growing social and economic burden [7]. Recently 
approved treatments for ALS only marginally influence survival (rilu-
zole) or disability progression (edaravone) [8,9]. This lack of thera-
peutic efficacy is probably due to the fact that the genetic and clinical 
landscape of ALS is very complex and clinical manifestations inherent to 
MN degeneration most likely reflect a variety of different upstream 
molecular pathomechanisms [10]. Indeed, mutations in more than 30 
genes have been implicated in ALS pathogenesis, therefore indicating 
that ALS is not a single disease but rather belongs to a disease spectrum. 
This fact must be considered in searching for disease-modifying treat-
ments, shifting from targeting common clinical manifestations to acting 
on the underlying molecular pathophysiology. Data from disease model 
systems, and from human biosamples, provide strong evidence in all 
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cases of ALS for defects in RNA metabolism, redox imbalance, inflam-
mation, and altered proteostasis, which exhibit a high degree of mo-
lecular connectivity and that are most likely related to the progressive 
loss of homeostatic functions. However, therapies targeting each of 
these pathways individually have consistently failed to produce robust 
evidence of benefit in the clinic. Therefore, a strategic shift in approach 
is needed to develop therapies which target these multiple pathophysi-
ological pathways together by reinforcing the endogenous homeostatic 
systems. A very promising strategy is the activation of transcription 
factor NRF2 (nuclear factor (erythroid-derived 2)-like 2), nowadays 
recognized as a master regulator of multiple cytoprotective responses. 
NRF2 is ubiquitously expressed [11], but at different levels depending 
on the cell type. Glial cells exhibit more robust NRF2 expression than 
neuronal cells [12]. Therefore, the role of NRF2 in astrocytes and 
microglia is expected to be especially relevant to the health of MN, 
combining both direct and indirect mechanisms. 
2. Genetic alterations associated with ALS 
Most ALS cases are considered sporadic (SALS), but 5–10 % are fa-
milial (FALS), usually with autosomal dominant inheritance. More than 
30 genes have been identified as causative for ALS and the genetic cause 
can now be identified in 60–70 % of familial ALS cases [13]. Moreover, 
large-scale genome-wide association studies (GWAS) of apparently 
SALS, without a family history, indicates a genetic variability for these 
patients, based predominantly on rare variants. Thus, one recent study 
showed clinically reportable causative genetic changes in 21 % of ALS 
patients, only 7 % of whom had a positive family history, and a further 
21 % of cases had variants of unconfirmed significance after removal of 
benign or non-specific variants [14]. 
The most common genetic cause of ALS is a hexanucleotide expan-
sion in the first intron of the C9ORF72 gene, present in approximately 
40 % of FALS cases and 7 % of SALS cases [15]. Mutations in SOD1, 
TARDBP and FUS are the next most frequent, and are present in 
respectively 20 %, 4 % and 4 % of FALS cases, and in some sporadic cases 
[16] (Fig. 1A). Other reported ALS genes are less common and partici-
pate in the disruption of various cellular pathways, including RNA 
processing, endosomal trafficking, autophagy/protein homeostasis, 
mitochondrial integrity, and cytoskeletal function/axonal transport 
[17]. Beyond TARDP43 and FUS, exome sequencing studies revealed 
mutations in other genes involved in RNA metabolism, such as MATR3 
[18], hnRNPA2B1 and hnRNPA1 [19]. These studies have led to an 
increased interest in the role of RNA metabolism in ALS. 
3. ALS mouse models 
The predominant approach to modelling the pathology of ALS has 
relied on the use of genetic mouse models with transgenic (over) 
expression of human mutant ALS associated genes that cause profound 
phenotypes. More recently, knock-in approaches have begun to yield 
more physiological models, but with milder phenotypes. Transgenic 
overexpression of the human SOD1 gene with disease-relevant muta-
tions is the first described and to-date most extensively studied model. In 
1994, humanized mice carrying a human SOD1 transgene with the G93A 
mutation under control of the human SOD1 promoter were reported 
[20]. These mice displayed a motor phenotype with significant loss of 
spinal MN. This model provided evidence that SOD1 mutations lead to a 
toxic gain of function [20] and has led to multiple observations related 
to ALS pathophysiology. These include the concept of non-cell autono-
mous MN degeneration [21], the role of glial inflammation in driving 
disease progression [22], the contribution of SOD1 misfolding and ag-
gregation to pathology [23], and validation of Neurofilament Light 
Chain levels as biomarkers of MN degeneration [24]. Mice expressing 
the wild-type sequence with a similar expression level lacked a 
discernible phenotype [20], although a mild phenotype has been seen in 
subsequent studies [25]. Controversy surrounds the use of this model, 
particularly in regard to replication of the effects of pharmacological 
agents in different laboratories. However, these issues seem to be related 
predominantly to differences in study design [26]. 
After the identification of TDP-43 proteinopathy as a characteristic 
feature of ALS [27] and the identification of mutations in its coding 
gene, TARDBP, as causative in a small proportion of cases [28], human 
TDP-43 transgenic mice with mutant specific phenotype were gener-
ated. This was an imperative because essentially all ALS cases carry 
TDP-43 proteinopathy, except for patients with mutations in SOD1 and 
FUS [29], suggesting a mechanistic difference in MN degeneration 
driven by these gene mutations. Transgenic overexpression above a 
certain threshold of either wild-type or mutant TDP-43 led to significant 
MN degeneration and severe phenotypes [30,31]. Interestingly, more 
physiological levels of expression, generated milder phenotypes that 
included MN degeneration in the absence of toxic protein aggregates, 
suggesting that proteinopathy may only be prevalent at later stages of 
Fig. 1. Overview of ALS human genetics 
and mouse models. A, familiar ALS (FALS) 
represents the 5–10 % of the total cases, 
usually with autosomal dominant inher-
itance. The hexanucleotide expansion of 
the C9ORF72 gene is present in approx-
imately 40 % of FALS cases. Mutations in 
SOD1, TARDBP and FUS represent 20 %, 
4 % and 4 % of FALS cases, respectively. 
Other ALS genes are less common and 
are implicated in disruption of various 
cellular pathways. B, the discovery of 
these genes has allowed the development 
of enormously useful mouse models in 
preclinical research. The figure illus-
trates representative hallmarks of each 
mouse model.   
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disease [32]. Similar results are replicated in mouse models carrying 
knock-in mutations of the murine Tardbp gene, which show milder 
neurodegeneration, no proteinopathy and a mixed ALS/FTD phenotype 
[33]. 
To date several groups have generated FUS over-expressing mice. 
Recombinant adeno-associated viruses have been used to express V5- 
tagged human wild type or mutant FUSR521C or FUSΔ14 (which lacks 
the nuclear localization signal) in neurons of the mouse brain. Although 
these mice do not model ALS, this study showed that the cytoplasmic 
accumulation of mutant FUS versions was higher than the wild type 
version. In fact, over-expression of FUSΔ14, recapitulated many aspects 
of FUS proteinopathies, including insoluble aggregates of FUS, ubiq-
uitin, p62/SQSTM1, α-internexin, and the poly-adenylate(A)-binding 
protein 1 (PABP-1). However, TDP-43 did not localize to these in-
clusions [34]. Regarding FUS transgenic mice, it is interesting that 
whereas the homozygous mice overexpressing the wild type FUS under 
the control of a modified mouse prion promoter exhibit profound neu-
rodegeneration, hemizygous mice are unaffected. Despite that total FUS 
levels and subcellular location was similar in both genotypes, homozy-
gous mice showed severe motor dysfunction with a 60 % loss of lower 
MNs. At the cellular level, these mice exhibited FUS-positive, ubiq-
uitin-negative cytoplasmic inclusions in surviving motor neurons of the 
spinal cord, as well as glial activation [34]. In a recent study, the phe-
notypes of FUS knock-in mice expressing miss-localized cytoplasmic FUS 
and complete FUS knockout mice has been compared. Interestingly, FUS 
knock-in mice exhibited a reduced number of MN at birth, associated 
with exacerbated MN apoptosis, which was rescued by neuron-specific 
CRE-mediated expression of wild type FUS. These studies suggest that 
in addition to FUS nuclear loss of function, cytoplasmic accumulation of 
FUS leads to MN death through a toxic gain of function [35]. Over-
expression of a truncated version of FUS (FUS(1-359)) lacking the nuclear 
localization signal leads to synaptic and dendritic spine dysfunction in 
the frontal cortex before neuronal loss, recapitulating some phenotypic 
features of ALS related to disruption of dendritic homeostasis [36]. The 
transcriptional profile of FUS(1-359) transgenic mice was analyzed by 
RNA-seq. The resulting data show that, prior to clinical symptoms, 
FUS-mediated miss-localization is asymptomatic until it reaches the 
terminal stage of disease progression. Massive FUS-positive inclusions 
were detected in spinal cord after this time, accompanied by a tran-
scriptional shift including acquisition of pro-inflammatory phenotype of 
microglia and malfunction of cholinergic transmission in MNs [37]. 
Other murine models replicate MATR3 mutations. Mice expressing 
human MATR3 protein in either wild type or mutant MATR3F115C under 
the control of the mouse prion promoter exhibit robust expression of the 
transgenic mRNA in muscle but minimal in spinal cord. Whereas the 
lifespan of mice expressing wild type MATR3 is more than 20 months 
with no change in motor tests performance, MATR3F115C mice exhibit 
weak limbs earlier than 1 month of age. Although the muscle fibers of 
both mice showed an increase in the number of vacuoles in an age- 
dependent manner, vacuolation was noticeably more severe in 
MATR3F115C mice [38]. CRISPR/Cas9 technology has allowed the gen-
eration of a new MATR3S85C knock-in mouse. Interestingly, these mice 
recapitulate behavioral and neuropathological features of early-stage 
ALS such as motor impairment, muscle atrophy, neuromuscular junc-
tion defects, Purkinje cell degeneration and neuroinflammation in the 
cerebellum and spinal cord and emerge as a promising tool for pre-
clinical studies [39]. 
After the identification of hexanucleotide repeat expansions in 
C9ORF72, a range of BAC transgenic mice have been generated carrying 
the full-length gene from an ALS patient with up to 500 repeats. Multiple 
studies show in these mice a molecular phenotype characterized by RNA 
foci and Dipeptide Repeated Protein (DPR) expression [40–42], but only 
one model demonstrated a significant motor phenotype [42]. Never-
theless, behavioral findings are under dispute due to variable outcomes 
between different laboratories [43,44]. Other strategies for replicating 
DPR toxicity include viral mediated over-expression of DPR producing 
transgenes [45,46] (Fig. 1B). As we will discuss, the use of these animal 
models contributed immensely to our understanding of ALS pathology, 
allowing the identification of therapeutic molecular targets. 
4. NRF2 regulation and ARE-gene targets 
The transcription factor NRF2 is a basic region-leucine zipper tran-
scription factor that forms heterodimers with small musculo- 
aponeurotic fibrosarcoma proteins (MAFs) in the nucleus. The hetero-
dimer recognizes an enhancer sequence termed Antioxidant Response 
Element (ARE) that is present in the regulatory regions of approximately 
250 genes (ARE-genes). ARE-genes encode a broad network of enzymes 
involved in phase I, II, and III biotransformation reactions, antioxidant 
mechanisms encompassing NADPH, glutathione- and thioredoxin- 
mediated reactions, lipid and iron catabolism, interaction with other 
transcription factors, and autophagy gene expression. These pleiotropic 
actions lead to significant neuroprotective effects. Attenuation of the 
NRF2 response has been observed in ALS [47,48]. In human biosamples, 
biochemical evidence also indicates that reduced NRF2 activity is a 
hallmark of ALS [49,50]. Importantly, the observed attenuation of NRF2 
responses can be overcome pharmacologically as will be described later. 
NRF2 is continuously synthesized and degraded, exhibiting a half- 
life of just 20–30 min depending on the cell type [51]. This apparently 
futile cycle allows cells to rapidly respond to insults and, through its 
transcriptional network, coordinate multifaceted responses for main-
taining a stable internal environment. NRF2 stability is controlled at 
least by three ubiquitin E3 ligase adapters: Kelch-like ECH-associated 
protein 1 (KEAP1) [52–54], beta-transducin repeat containing protein 
(β-TrCP) [55,56] and synoviolin E3 ubiquitin ligase (HDR1) [57], which 
target this protein for proteasomal degradation. The main and phar-
macologically most relevant mechanism of regulation of NRF2 stability 
is KEAP1. KEAP1 is a homodimeric E3 ligase adapter that presents NRF2 
to a complex formed by CULLIN3/RBX proteins, leading to its ubiq-
uitination and subsequent proteasomal degradation [58,59]. KEAP1 
binds one molecule of NRF2 at two amino acid sequences with low 
(aspartate, leucine, glycine; DLG) and high (glutamate, threonine, 
glycine, glutamate; ETGE) affinity [60]. There are two well established 
mechanisms of KEAP1 regulation. The canonical pathway is based on 
the fact that KEAP1 is an electrophilic sensor that contains several 
electrophile- and redox-sensitive cysteine residues. Ectopic or endoge-
nous electrophiles, modify sulfhydryl groups of specific redox-sensitive 
cysteines of KEAP1, including C151, C273, and C288 [61]. Following 
these cysteine modifications KEAP1 is no longer capable of presenting 
NRF2 for ubiquitination [62]. As a result, newly synthetized NRF2 es-
capes KEAP1-dependent degradation, translocates to the nucleus, and 
activates ARE genes (Fig. 2). In the non-canonical pathway, KEAP1 is 
sent to autophagy degradation through interaction with the autophagy 
carrier protein SQSTM1 [63]. This protein contains an STGE motif that, 
upon serine phosphorylation by several signaling kinases such as casein 
kinase 1 (CK1), transforming growth factor beta-activated kinase 1 
(TAK1), mTORC1 and PKCσ [64–67] resembles the high affinity ETGE 
motif of NRF2. Then, by binding to KEAP1, SQSTM1 leads to autophagic 
degradation of KEAP1, relieving NRF2 from KEAP1-mediated repres-
sion. Importantly, mutations affecting SQSTM1 have been implicated in 
both ALS and frontotemporal dementia [68] (Fig. 3). 
5. Dysregulation of the NRF2 in ALS 
Although studies employing NRF2-null mice backcrossed with ALS- 
mice reported only a modest protection of NRF2 to disease hallmarks, 
probably due to compensatory mechanisms [69,70], strong evidence 
indicates that NRF2 activity decreases in ALS models and patients. Pri-
mary MN cultures from SOD1G93A transgenic mice showed reduced 
NRF2 levels compared with those from wild type littermates [71]. 
Accordingly, motor neuron-like NSC34 cells overexpressing mutant 
human SOD1 revealed downregulation of the NRF2 transcriptional 
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signature [47]. A different approach has consisted on developing ALS 
pathology in mice expressing a reporter cassette of ARE-driven human 
placental alkaline phosphatase. The authors showed an early and 
intense NRF2 activation in skeletal muscles, but a lower level of acti-
vation at symptoms onset in spinal cord MNs and astrocytes [72]. A MNs 
transcriptomic study investigating differences between two strains of 
SOD1 transgenic mice with fast and slow disease progression showed 
that the fast-progressing strain (129Sv) had a much weaker NRF2 
response compared to the slow-progressing strain (C57bl/6) [73]. 
Strong evidence for a role of NRF2 in ALS comes from genetic studies 
performed in 522 sporadic ALS patients compared with 564 asymp-
tomatic controls. One NFE2L2 haplotype was associated with decreased 
risk of ALS while one haplotype in KEAP1 correlated with later ALS 
onset. Importantly the NFE2L2 haplotype, which includes three func-
tional promoter SNPs associated with high NRF2 protein expression, 
correlated with four years later disease onset [50]. Among the new genes 
associated with ALS, 10 mutations in the SQSTM1 gene, comprising 9 
heterozygous missense mismatches and 1 deletion, have been found in 
both sporadic and familial forms of ALS. Interestingly, predictive in silico 
analysis classified 8 of the 9 missense variants as pathogenic. This 
finding links NRF2/KEAP1/autophagy with ALS pathology, suggesting 
that NRF2-mediated regulation of protein degradation might represent 
an important therapeutic target to combat ALS [74]. NRF2 and KEAP1 
expression levels were analyzed in postmortem samples of primary motor 
Fig. 2. Transcriptional program coordinated by NRF2 to underpin a protective response. Newly synthetized NRF2 in neurons and glial cells is constantly targeted for 
degradation by the action of the indicated E3-ligase adaptors. Under several stimuli, these E3-ligases could be inhibited and NRF2 escapes degradation. Then, NRF2 
enters the nucleus and heterodimerizes with the members of small MAF family through their bZip domain. The heterodimer binds to an enhancer sequence termed 
Antioxidant Response Element (ARE) that is present in the regulatory regions of over 250 genes (ARE genes). These genes participate in the control of redox, 
inflammation, metabolism and proteostasis functions, as indicated. Activation of this NRF2-ARE response favors a cytoprotective wave. ATG-7, autophagy related 7; 
FAS, fatty acid synthase; GCL, glutamyl cysteine ligase; Gpx, glutathione peroxidase; Gpx8, glutathione peroxidase; GST, glutathione S-Transferase; G6PDH, glucose- 
6-phosphate dehydrogenase; γGS, γ-glutamate cysteine synthetase; HO1, heme oxygenase-1; IL1β, interleukin 1 beta; IL6, interleukin 6; IL17D; interleukin 17D; 
MARCO, macrophage receptor with collagenous structure; ME, malic enzyme; NQO1, NADPH quinone oxidase 1; NDP52, calcium-binding and coiled-coil domain- 
containing protein 2; PSMB1, proteasome subunit b type-1; POMP, proteasome maturation protein; PGD, phosphogluconate dehydrogenase; SQSTM1, sequestosome 
1/p62; ULK1, unc-51 like autophagy activating kinase 1. 
Fig. 3. ALS-related SQSTM1 mutations impair feedforward loop in the SQSTM1/KEAP1/NRF2 pathway. In the normal situation (left panel), NRF2 is activated upon 
oxidative stress and enters the nucleus to drive ARE genes transcription, which gives rise to SQSTM1 synthesis. Phosphorylated SQSTM1 binds KEAP1, targeting it for 
autophagic degradation and thus enhancing the NRF2 response. In SQSTM1-related ALS (right panel) mutations in SQSTM1 (mSQSTM1) either impede its phos-
phorylation or binding to KEAP1, hindering its autophagosome degradation, and increasing repression of NRF2 signaling. 
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cortex and spinal cord [75]. Compared to controls, NRF2 mRNA and 
protein levels were reduced in spinal cord, whereas KEAP1 mRNA levels 
were increased in the motor cortex. Because the postmortem studies were 
performed at the terminal stage of ALS, NRF2 reduction does not exclude 
the possibility that the NRF2 axis could be activated at onset or at early 
ALS stages. Nevertheless, these results suggest that alterations in this 
signaling pathway occur in MNs of ALS patients and that they may 
contribute to chronic MN degeneration. The NRF2 target gene encoding 
Peroxiredoxin 3 (PRX3), is also downregulated in spinal MNs from 
sporadic and SOD1-related MN degeneration, suggesting the disruption 
of mitochondrial antioxidant defense as an alternative mechanism to 
generate oxidative stress within these cells [48]. In fact, evaluation of 
temporal and spatial changes of KEAP1, NRF2 and its downstream 
response proteins Heme oxygenase-1, Thioredoxin, and Heat shock 
protein 70 (HO-1, TRX, and HSP70, respectively) throughout the MN 
degeneration in the spinal cord of ALS model mice revealed that, while 
KEAP1 protein levels progressively decreased from early to late symp-
tomatic stages, in parallel NRF2 dramatically increased in the anterior 
lumbar cord with accumulation in the MN nucleus and in glial cells. In 
contrast, downstream stress response proteins showed only a small in-
crease in MNs that correlated with increased number of glial cells after 
the symptomatic stage [76]. Altogether, these studies support the hy-
pothesis that reinforcement of NRF2 activity could represent a prom-
ising therapeutic strategy for neuroprotection in ALS. 
It is not clear yet how the NRF2 signature is altered in ALS and this 
fact might be related to RNA handling. In Neuro2A, SH-SY5Y and 
HEK293 cell lines as well as in ALS spinal cord samples, the RNA binding 
protein RBM45 is redistributed from the nucleus to the cytosol after 
oxidative insult, accompanied by KEAP1 binding. The functional con-
sequences of this interaction were analyzed in HEK293 cells showing 
that RBM45 stabilized KEAP1 with consequent dampening of the tran-
scription of an ARE-reporter [77]. Moreover, RNA binding immuno-
precipitation studies in patient fibroblasts revealed robust enrichment of 
NFE2L2 and GPX1 (glutathione peroxidase 1) transcripts bound to 
hnRNP K protein in TDP-43 mutant cells. Despite the elevated expres-
sion of several antioxidant transcripts, glutathione levels were reduced 
in TDP-43M337V patient fibroblasts and astrocyte cultures from 
TDP-43Q331K mice compared with control cells, indicating elevated 
oxidative stress and failure of some upregulated antioxidant genes to be 
properly translated into protein [78]. 
6. Molecular hallmarks of ALS associated with insufficient NRF2 
activation 
The variety of biological pathways affected by multiple FALS-related 
genes reveals the complex etiology of this disease [10,79]. Importantly, 
the genetic heterogeneity of ALS inferred from genomics is also mirrored 
by transcriptomics studies. To determine whether NRF2 could be crucial 
in combating ALS molecular hallmarks, we screened microarray and 
RNA-seq public datasets generated from spinal cord, brain cortex and 
MNs differentiated from induced pluripotent stem cells. In total, we 
downloaded 9 lists of differentially expressed genes in neural tissue or 
cells implicated in ALS alterations (Table 1) [80–87]. As shown in Fig. 4, 
analysis of the dysregulated genes by Gene Ontology Biological Process 
enrichment depicted several altered pathways including cell death/-
cycle, signaling, immune response, subcellular localization, neuro-
development and migration, adhesion, proteostasis, response to oxygen 
levels alterations, vascular homeostasis, and RNA metabolism. This 
analysis provides a starting point to discuss the role of these pathways in 
the pathogenesis of ALS and the possible contribution of dysregulated 
NRF2 to some of them. Although excitotoxicity was not detected at the 
transcriptomic level, we will address it because of the involvement of 
NRF2. 
6.1. Redox control 
Dysregulation of the antioxidant defenses and increased production 
of reactive oxygen species (ROS) contribute to progression of neurode-
generative disease. The analysis of cerebrospinal fluid (CSF), blood and 
tissue samples from ALS patients shows evidence of oxidative stress and 
provide reliable biomarkers. Most studies have focused on the identifi-
cation of oxidized macromolecules or antioxidant capacity. Thus, the 
lipid peroxide 4-hydroxynonenal (HNE) [88], was significantly 
increased in the CSF of SALS patients compared to patients with other 
central nervous system diseases [89,90], although this finding was not 
reproduced in another study [91]. Lipid peroxidation levels were also 
increased in plasma and serum [92] but were not modified by riluzole, 
further highlighting the need for combined therapies. In addition, 
lumbar spinal cord from ALS patients exhibited increased 
HNE-peroxidated products measured by immunohistochemistry [93, 
94], as well as malondialdehyde [95,96]. The increase in lipid per-
oxidated products is also found at late stages in the spinal cord of the 
SOD1G93A mice, indicating that oxidative stress is a common mechanism 
for MN degeneration in animal models and patients [97,98]. 
The levels of 3-nitrotyrosine (3NT), a post-translational protein 
marker of nitrosative stress, are extensively altered in ALS [99,100]. 
3NT is increased in the CSF [101] and in the spinal cord of ALS patients 
[102], and in one study this was accompanied by a concomitant increase 
in the expression of the inducible isoform of nitric oxide synthase (iNOS) 
[103]. Increased nitrosative stress could lead to further oxidative stress 
in a positive feedforward loop, because nitrosylated SOD2 was signifi-
cantly enriched in CSF [104] and it is known that nitrosylated forms of 
SOD2 are inactive [105]. 
Table 1 
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a The study by Aronica et al. depicted two different subsets of sALS patients 
based in their different transcriptional signatures. In this analysis we used both 
subsets as separated entities two construct gene ontology network. 
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c Statistical stringencies of the original studies were used to filter DEGs genes. 
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HNE activates NRF2 in HeLa cells [106] and in rat L2 provokes the 
NRF2-dependent activation of glutathione synthesis [107]. More in the 
context of ALS, NRF2 protects from the nitrosative stress produced by 
spinal cord astrocytes of SOD1G93A mice in vitro by inducing glutathione 
biosynthesis [108]. By contrast, reduction of the glutathione pool in the 
SOD1G93A mice and in knock-out mice for Gclm (Glutamate-Cysteine 
Ligase Modifier Subunit) worsens the course of the disease. Activation of 
glutathione synthesis and use with NRF2 activators could help indirectly 
against other ALS pathological hallmarks that are in part caused by 
oxidative stress. For example, HNE produces the partial cytoplasmic 
localization of TDP-43 in vitro, resembling what happens in ALS-related 
MN injury [109] but treatment of TDP43A315T-expressing NSC34 cells 
with glutathione monomethyl ester decreases in TDP-43 nuclear clear-
ance and induces cytoplasmic accumulation [110]. 
6.2. Resolution of inflammation 
Changes in the immune response associated with ALS are not simply 
a consequence of MN degeneration, but actively contribute to disease 
progression. In the early stages of disease, resident glial cells and infil-
trating T-lymphocytes may display protective programs aimed at 
mounting a neuroprotective response, while at later disease stages, 
persistent inflammation contributes to damaging MNs, and accelerates 
disease progression [111]. Numerous preclinical studies have reported 
that activation of NRF2 leads to potent anti-inflammatory effects in 
myeloid leukocytes [112], macrophages [113] and glial cells [114,115]. 
In observational studies, a polymorphism in NFE2L2 was associated with 
reduced transcriptional activity, correlating with increased risk of in-
flammatory disease [116]. 
Fig. 4. Network analysis of dysregulated pathways in ALS. Lists of dysregulated genes from several ALS transcriptomic studies were subjected to overrepresentation 
analysis of Gene Ontology (GO) Biological Process Slim (April 2021 release) in Cytoscape using BinGO plugin [262]. Then, EnrichmentMap plugin [263] was used to 
produce a network of overrepresented terms across all studies. A q-value (FDR-adjusted p-value) < 0.01 was used as an statistically significance threshold for term 
enrichment. Only terms overrepresented in at least two lists of dysregulated genes were used to construct the GO term network. The color of each node represents the 
number of dysregulated-gene lists in which the gene ontology term is enriched. (For interpretation of the references to color in this figure legend, the reader is 
referred to the Web version of this article.) 
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Nuclear factor-kappa B (NF-κB), a master regulator of inflammation, 
is upregulated in the spinal cord of ALS patients [117] and SOD1G93A 
mice [118]. NRF2 and NF-kB crosstalk through feedforward and feed-
back mechanisms. Both transcription factors compete for the same 
coactivator, CBP/p300, shifting the transcriptional activity in favor of 
the most abundant factor within the nucleus. Additionally, NF-kB may 
promote interaction of histone deacetylase-3 with small MAF proteins, 
therefore preventing their dimerization with NRF2 [119]. NF-kB binds 
and translocates KEAP1 to the nucleus, thus favoring NRF2 ubiquitina-
tion and degradation in this cellular compartment [120]. On the other 
hand, NFE2L2 transcription is activated by NF-kB, thus inducing a 
negative feedback loop [121]. The E3 ligase adapter β-TrCP tags both 
IkBα [122] and NRF2 [55,56] for proteasomal degradation, and this can 
lead to increased NF-kB activity. Various pro-inflammatory signals 
activate the Rho GTPase RAC1, which leads to NF-kB and NRF2 acti-
vation. Then, NRF2 inhibits RAC1-mediated activation of NF-kB [123]. 
NF-κB inhibition in microglia could be considered a molecular mecha-
nism to delay MN injury. Thus, selective NF-κB inhibition in microglia 
rescued MNs from microglial-mediated death in vitro and extended 
survival in SOD1 mice. In contrast, constitutive activation of NF-κB 
selectively in myeloid cells of wild type mice produces some of the 
pathological features of ALS in the spinal cord including gliosis and MN 
death [124]. 
Secreted mSOD1 and mTDP-43 proteins, and lyso- 
phosphatidylcholine, a lipid related to neurodegeneration, may act as 
a damage-associated molecular pattern (DAMP), triggering inflamma-
some activation [125–127]. The NLRP3 inflammasome is a multiprotein 
complex that activates caspase-1 and promotes the processing of the 
pro-inflammatory cytokine IL-1β. A growing body of evidence supports 
the concept that NRF2 activation attenuates NLRP3 inflammasome 
activation in monocytes, macrophages, and microglia [128,129]. 
Accordingly, NRF2-null mice exhibit enhanced brain NLRP3 inflam-
masome activation and neuroinflammation [130]. Cooperating with 
NLRP3 inhibition, NRF2 can also inhibit the recruitment of RNA pol II to 
the promoter region of the pro-inflammatory IL6 and IL1β genes, 
repressing their transcription upon LPS stimulation [131]. 
The role of TGF-β1 in ALS has been extensively studied. Serum and 
CSF of ALS patients show elevated TGF-β1 levels that correlate with a 
more aggressive disease course [132]. Astrocytes from ALS patients and 
SOD1G93A mice also express high TGF-β1 levels. On the contrary, abla-
tion of SOD1G93A expression in astrocytes decreased TGF-β1 levels and 
slowed disease progression [133]. Although in the central nervous sys-
tem the relationship between NRF2 with TGF-β1 is still unknown, in 
liver NRF2 suppresses the profibrotic TGF-β1/Smad3 pathway [134]. 
Considering that ALS progression is slowed by pharmacological inhibi-
tion of TGF-β1, increasing the survival of SOD1G93A mice [133], NRF2 
activation might provide a strategy to attenuate the over-production of 
TGF-β1. 
Upon stimulation microglia acquire a dynamic state ranging from 
pro-inflammatory (M1-classic) to the wound healing/neuroprotective 
(M2-alternative) phenotypes, depending on the disease stage and sur-
rounding environmental triggers. Microglial activation can be detected 
by position emission tomography imaging in ALS patients using a spe-
cific radioligand for the peripheral benzodiazepine binding site, [11C] 
(R)-PK11195. This signal is significantly increased in motor cortex, 
pons, and thalamus in ALS patients, with significant correlation between 
binding in the motor cortex and the burden of upper MN clinical features 
[135]. The M1/M2 balance is altered in microglia derived from 
SOD1G93A mice. At early disease stages, microglial cells exhibit high 
M2-markers (Ym1, CD163 and Bdnf) and low M1-inflammatory markers 
(Nox2) compared to end-stage disease [136]. NRF2 also induces an 
anti-inflammatory phenotype modulating the M1/M2 phenotypes [137, 
138]. The modulation of the glutathione pool exerted by NRF2 is 
instrumental in determining the microglial phenotype. NRF2 activation 
reinforces cysteine and glutathione levels through upregulation of the 
cystine/glutamate transporter and the glutamate-cysteine ligase 
catalytic and modulatory subunits (GCLC and GCLM, respectively) 
leading to acquisition of the anti-inflammatory M2-phenotype. On the 
contrary, glutathione depletion sensitizes macrophages to LPS-induced 
inflammation [139]. 
In summary, these studies indicate that NRF2 is a plausible candidate 
to modulate the microglial fate in ALS. The benefits of the M2-phenotype 
have been recently described employing induced pluripotent stem cells 
from ALS patients. M2-induced cells suppressed pro-inflammatory me-
diators (IL-6 and TNF-α) released by M1-like cells and reduced the 
proliferation of effector T cells. Moreover, M2-derived cells transformed 
effector T cells into regulatory T cells promoting beneficial immuno-
modulatory effects [140]. Overall, these studies point towards a key role 
of NRF2 as a modulator of the inflammatory response and highlight an 
important aspect of the therapeutic potential of NRF2 activation in ALS. 
6.3. Protein quality control 
The KEAP1/NRF2 pathway has been considered for many years a 
defense mechanism against oxidative stress, but recent evidence has put 
this pathway at the center of an overall cellular stress-response, which is 
tightly linked with regulation of proteostasis. Indeed, dysregulation of 
protein folding, and degradation is common to several neurodegenera-
tive diseases, which display characteristic protein aggregates such as 
amyloid-β and Tau (AD), α-synuclein (PD) or TDP-43 (FTD/ALS) among 
others. NRF2 and proteostasis intersect through direct interaction be-
tween SQSTM1 and KEAP1. As highlighted above, in the non-canonical 
pathway, KEAP1 is tagged by SQSTM1 and redirected for autophagic 
degradation, thus leaving NRF2 free to accumulate and translocate to 
the nucleus [63]. The link between NRF2 and proteostasis, however, is 
twofold, as NRF2 also transcriptionally regulates several genes involved 
in the un-folded protein response (UPR), the ubiquitin proteasome sys-
tem (UPS) and autophagy [141]. 
Since mutations in SQSTM1 are associated with ALS, it is likely that 
also the NRF2 pathway is affected due to impairment of the SQSTM1- 
KEAP1 interaction [142], leading to downregulation of the antioxi-
dant response. Interestingly, disruption of the SQSTM1/KEAP1 inter-
action is a common hallmark in SQSTM1-related ALS. Thus, P348L and 
G351A mutations in SQSTM1, located in the KEAP1-interaction domain, 
produce reduced binding to KEAP1 and thus a decrease in the activation 
of NRF2 as measured in ARE-luciferase reporter assays [143]. Similarly, 
the R110C mutation produces a decrease in the phosphorylation of Ser 
403 and Ser 349 [144], which are needed for the SQSTM1/KEAP1 
interaction [67], also resulting in impaired NRF2 activity. Neurons with 
mutated SQSTM1, exhibit an increase in stress granules, cytoplasmic 
TDP-43 aggregates, and abnormal dendrite morphology [142]. Consis-
tently, NRF2 downregulation exacerbates the impairment in protein 
degradation, resulting in misfolded protein accumulation and 
proteotoxicity. 
A further link between TDP-43 proteinopathy and dysregulation of 
the NRF2 pathway was highlighted in NSC34 cells expression mutant 
TDP-43M337V. Interestingly, these cells showed increased nuclear accu-
mulation of NRF2 and downregulation of its target genes [145]. These 
opposing effects were caused by reduced expression of the NRF2 
trans-activators MAFK and Jun dimerization protein (JDP2). Similarly, 
mutant TDP-43 interacts with hnRNPK, which, in turns, binds 
NRF2-regulated transcripts, blocking their translation into proteins and 
leading to downregulation of the antioxidant repose [78]. 
Interestingly, C9ORF72-linked ALS mutations, as well as other vari-
ants of ALS, display autophagy impairment and SQSTM1 accumulation. 
SQSTM1 cytosolic accumulation might lead to constitutive activation of 
NRF2 via the non-canonical pathway and, consequently, of its down-
stream gene targets. Studies in Atg7-deficient mice, displaying severe 
autophagy defects, not only feature SQSTM1 accumulation and consti-
tutive NRF2 activation, but also increased levels of polyubiquitylated 
protein aggregates and inclusion bodies [146]. Surprisingly, these can 
be completely suppressed by either SQSTM1 or NRF2 downregulation. 
J. Jiménez-Villegas et al.                                                                                                                                                                                                                      
Free Radical Biology and Medicine 173 (2021) 125–141
132
This effect has been associated with the ability of NRF2 to transcrip-
tionally regulate genes involved in protein ubiquitination [147] as a 
stress-response mechanism. These studies indicate that NRF2 activation 
in the treatment of ALS needs to be aimed at restoring homeostatic 
balance, as NRF2 deficiency, as well as hyperactivation, can lead to 
significant proteostasis defects. 
6.4. RNA processing 
The identification of mutations in RNA binding proteins such as TDP- 
43 and FUS, involved directly in RNA metabolism, and in C9orf72 which 
leads to both sequestration of RNA binding proteins and disruption of 
nucleocytoplasmic transport, suggest a key pathogenic mechanism in 
ALS [148]. Appropriate processing and control of RNA splicing, trans-
port and stability is essential for neuronal health. As discussed previ-
ously, some of these mechanisms mediate the transcriptional 
dysregulation of NRF2 target genes [47,78]. This finding suggests a 
straightforward strategy for overcoming this dysregulation by 
enhancing NRF2 activation [48]. 
Various RNA binding proteins important in RNA metabolism and 
processing undergo changes in subcellular localization during stress. 
This is the case for sodium arsenite-induced translocation of TDP-43 
from the nucleus into stress granules as a result of oxidative stress 
[149]. These stress granules form as a result of liquid-liquid phase sep-
aration, and long-term arsenite treatment leads to formation of a sepa-
rated phase of TDP-43 droplets that lose their liquid-like state and transit 
to gels or solids likely enabling TDP-43 aggregation [150]. 
Considering that oxidative stress deeply impacts in microRNAs 
(miRs) dynamics, it could be expected that miRs modulate in part the 
NRF2-driven cytoprotective program. In fact, it is a two-direction way in 
which miRs directly or indirectly target NRF2 but also NRF2 modulate 
miRs biogenesis. Proper stress granule formation and complete matu-
ration of miRs require the coordinated action of a multiprotein complex 
which includes the ribonuclease type III, DICER. Conditional inactiva-
tion of DICER in MNs is enough to cause spinal neurodegeneration in 
vivo [151]. Accordingly, laser capture microdissection demonstrates that 
total miRs levels are reduced in MNs isolated from the lumbar spinal 
cord SALS patients [152]. Very relevant, the 5′-flaking region of human 
and mouse DICER gene contains an ARE site [153]. Since enhancing 
DICER activity is beneficial for MN function in two independent ALS 
mouse models [152], we speculate that activation of NRF2 could 
ameliorate DICER reduction improving MN function. 
NRF2 modulates the levels of miR-106b-25 cluster through a 
harmonized action with ATF4 in response to UPR, repression of the miR- 
106b-25 cluster increases the levels of the apoptotic protein BIM. Some 
evidence supports the relevance of this axis in ALS pathology. First, UPR 
response has been strongly associated with MN degeneration [154]. 
Second, the downregulation of miR-106b-25 cluster has been reported in 
the symptomatic stage of SOD1G86R mice together with BIM upregula-
tion [155], while BIM ablation reduced cellular apoptosis in the ventral 
horn of a transgenic mouse model of FALS, increasing their lifespan 
[156]. Finally, ALS patients show a misbalance between ATF4/NRF2 
expression since they exhibited upregulation of ATF4 [157] and 
downregulation of NRF2 as discussed above. Altogether, these obser-
vations provide a rational for NRF2 activation to reinforce crucial 
players of RNA metabolism. 
6.5. Intracellular transport 
Intracellular trafficking of vesicles and organelles is essential to 
maintain key cellular functions, such as metabolic homeostasis, protein 
synthesis and recycling, and membrane maintenance [158]. This 
cellular process is particularly important in neurons, which are highly 
specialized and compartmentalized cells. Neurons rely on axonal 
transport to shuttle mitochondria along the axon to provide the energy 
necessary for maintenance of membrane potentials, signal transduction 
and to transport vesicles and neurotransmitters [159]. This function is so 
essential for neurons that perturbation of this system is at the center of 
several neurodegenerative conditions [159]. 
Very relevant here, intracellular transport is highly sensitive to 
oxidative stress, in fact, hydrogen peroxide treatment of neurons leads to 
inhibition of axonal transport before any sign of neurodegeneration is 
observed [160]. Strikingly, studies in C. elegans have highlighted a 
strong link between NRF2 activation and synaptic activity [161]. 
Consistently, several findings have demonstrated that oxidative stress 
causes microtubule depolymerization, likely due to oxidation of cysteine 
residues on both α- and β-tubulin [162]. Particularly important in the 
context of ALS, glutathionylation of tubulin in MNs occurs during 
oxidative events, thus altering microtubule dynamics and structure 
[163]. Indeed, dysregulation of intracellular trafficking is a consistent 
characteristic of ALS, observed in transgenic SOD1 [164], TDP-43 [165] 
and C9orf72 mouse models [166], which all share dysregulation of the 
antioxidant response and NRF2 transcription [167,168]. Besides 
damaging microtubules and, thus, inhibiting axonal transport, oxidative 
stress has a direct impact on intracellular cargo trafficking, i.e. organ-
elles and vesicles shuttled within the cell. Compelling evidence indicates 
that oxidative stress causes mitochondrial damage [169], as well as ER 
stress and impairment of vesicle formation and trafficking [96]. In this 
context, activation of the antioxidant response through the NRF2 
pathway is likely to restore several mechanisms that impair intracellular 
trafficking. Indeed, activation of NRF2 has beneficial effects in a pre-
clinical model of tauopathy [170,171] and counteracts the adverse ef-
fects of hydrogen peroxide on axonal transport [160]. 
6.6. Angiogenesis and vascular homeostasis 
At least two angiogenic molecules, angiogenin (ANG) and vascular- 
endothelial growth factor (VEGF), are altered in ALS. First, several 
ANG mutations are causative of sporadic and familial cases of ALS 
[172]. Second, patients bearing a specific haplotype in the promoter 
region of the VEGF gene are at increased risk for developing ALS [173] at 
least in male patients [174]. In the same way, VEGF-deficiency in 
SOD1G93A mice worsens MN degeneration [175]. Together, the contri-
bution of these two genes to the pathophysiology of ALS underline the 
importance of angiogenesis in ALS. 
Both VEGF and ANG are hypoxia-inducible genes [176]. The master 
regulator of hypoxic response is Hypoxia inducible factor 1α (HIF1α), a 
transcription factor that undergoes stabilization in the absence of oxy-
gen, being key in the development of new blood vessels [177]. Inter-
estingly, both ALS patients and mouse models show HIF1α accumulation 
in spinal cord [178], suggesting an impairment in hypoxia-resolving 
abilities. This is supported by the low levels of ANG and VEGF pro-
teins in CSF from hypoxemic ALS patients compared to ALS controls 
[179], and by impairment in HIF1α transcription monocytes from ALS 
patients [180]. Indeed, recent in vivo studies using hypoxia-sensitive 
probes for positron emission tomography revealed that the spinal cord 
of ALS patients is under hypoxic-stress, maybe resulting impaired for-
mation of new blood vessels [181]. 
Although NRF2 also participates in angiogenesis, the direct crosstalk 
with HIF1α is complex [182]. For instance, fumaric acid esters, acting as 
activators of both NRF2 and HIF1α, promote the release of VEGF in 
astrocytes from wild type but not SOD1G93A mice, suggesting a limited 
response for the NRF2/HIF1α axis in ALS [183]. Much more established 
is the role of the NRF2 target HMOX1, encoding Heme oxygenase-1 
(HO-1). HO-1 catalyses the biotransformation of the heme group, with 
the aid of NADPH and O2, into bilirubin, carbon monoxide (CO) and free 
Fe2+ [184]. Interestingly, CO augments VEGF expression in vascular 
smooth muscle cells and endothelial cells [185,186], leading to angio-
genesis. HO-1 also functions downstream of VEGF signaling as it is 
crucial for formation of new vessels upon VEGF stimulation [187]. 
Similarly proper HO-1 catalytic activity is needed for HIF1α stabiliza-
tion, since Hmox1 knockout mice exhibit a decreased revascularization 
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after limb hypoxia [188]. 
Regression of the vascular network in spinal cord is a common 
hallmark of SOD1G93A and FUS(1-359) mice and precedes MN degenera-
tion [189,190]. Nevertheless, the vascular disturbances in these models, 
although fundamentally similar, display a different responsiveness to 
ANG treatment. On one hand, SOD1G93A benefit from exposure to ANG, 
exhibiting improved motor performance, survival and reduced vascular 
regression [191]. On the other, FUS(1-359) mice do not respond to ANG 
treatment [191]. This lack of responsiveness is probably due to the low 
expression of miR-126 in FUS(1-359) mice, which is abundant in endo-
thelial cells and is involved in angiogenesis [192] due sensitization to 
VEGF signaling. Hence, low miR-126 levels in FUS(1-359) mice would 
result in decreased angiogenic capacity and would hamper the thera-
peutic potential of ANG treatment. NRF2 activation with oxidized 1-pal-
mitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine upregulates miR- 
126 expression in HUVEC cells [193]. NRF2 activation renders endo-
thelial cells more responsive to angiogenic stimuli through miR-126 
upregulation, acting as an essential partner in a possible combination 
therapy. Importantly, miR-126 downregulation is partially responsible 
for other ALS hallmarks such as muscle denervation and axonal degen-
eration in the SODG93A mice, making NRF2-mediated activation of 
miR-126 a multi-hit strategy [194]. Moreover, miR-126 upregulates 
NRF2 in HUVEC cells [195], providing a positive feedback loop prob-
ably through upregulation of PI3K signaling [192]. 
6.7. Excitotoxicity 
Excitotoxicity is defined as the damage provoked in neurons due to 
an excessive increase in their excitatory inputs or a lack of the homeo-
static mechanisms needed to regulate this activity [196]. The mecha-
nisms involved in the death of neurons by excitotoxicity include a 
massive influx of Ca2+ ions that cannot be readily cleared. These ions 
accumulate in mitochondria and lead to energy failure and ROS over-
production [197]. Initial studies revealed an imbalance in the levels, 
metabolism and transport of glutamate, the main excitatory neuro-
transmitter in the CNS, suggesting a possible pathogenic role [198,199]. 
Furthermore, evidence from in vitro cultures suggested that cerebrospi-
nal fluid from ALS patients was toxic to cultured rat neurons in an AMPA 
glutamate receptor-dependent manner [200]. This imbalance in the 
glutamatergic system supported the therapeutic use of the anti-
glutamatergic agent riluzole, with modestly improves the survival of 
ALS patients [201]. 
NRF2 has been implicated in both basal susceptibility and inducible 
protection against excitotoxic damage. On one hand, hippocampal slices 
from NRF2-null mice displayed an increase in cell death upon exposure 
to kainate accompanied by an increase in oxidative stress [202]. On the 
other, activation of NRF2 by several compounds has provided protection 
against glutamate-mediated excitotoxicity, in in vitro cell cultures [203, 
204] and rat spinal cord explants [205]. Moreover, NRF2 activation also 
protected against the excitotoxic damage mediated by quinolinic acid, 
agonist of glutamate NMDA receptors [206], in rat cortical slices [207] 
or striatum [208]. 
Although some studies have pointed out the possible role of 
increased glutamate levels in ALS (reviewed in Ref. [209]), the major 
mechanisms driving excitotoxicity in this condition seems to be related 
to dysregulation of glutamate clearance attributed to a dysfunction or 
reduction in the levels of the main high affinity glutamate transporter, 
EAAT2 [209]. However, SOD1G93A causes a marked decrease in EAAT2 
levels at early disease stages in rats [210], but only at later stages of 
disease in mice [211–213]. In the first case, EAAT2 loss could operate to 
neurodegeneration, while in second case it may occur as a secondary 
result of earlier pathogenic events. In ALS patients, initial studies re-
ported a specific selective decrease in glutamate transport in synapto-
somes derived from motor and somatosensory cortex, and spinal cord, 
consistent with reduced EAAT2 levels at the same locations [214–216]. 
Oxidative stress impairs glutamate clearance in ALS in rat cortical 
astrocytes and mouse spinal cultures [217]. Mechanistically, 
EAAT2-mediated glutamate transport decreases in an oxidative envi-
ronment [218]. Interestingly, EAAT2 is modified by HNE in the lumbar 
spinal cord of ALS patients [218], suggesting feedforward loop between 
excitotoxicity and oxidative stress. NRF2 activation might break this 
injurious cycle, by reducing ROS levels and thus rendering EAAT2 more 
efficient at clearing extracellular glutamate. 
Several studies have highlighted the potential benefits of joined 
targeting of EAAT2 and NRF2 in ALS. One study using organotypic 
cultures of rat spinal cord revealed that combined treatment with rilu-
zole, which enhances EAAT2 transport [219] and the NRF2 activator 
sulforaphane provided superior protection against excitotoxicity 
compared to riluzole or sulforaphane. Similarly, combined lentiviral 
delivery of GDH2, EAAT2 and NFE2L2 genes in SOD1G93A mice delayed 
disease onset and improved survival better than each of these genes 
separately [220]. 
Extracellular glutamate and redox balance crosstalk at the level of 
the cysteine/glutamate antiporter SLC7A11, whose expression is upre-
gulated by NRF2. In astrocytes, this transporter imports cystine, the 
oxidized form of cysteine, in concert with the export of glutamate to the 
extracellular space [221]. Thus, an increase in the levels of EAAT2 could 
support cystine import that, upon reduction to two cysteines, will be 
used for glutathione synthesis [222]. Unfortunately, ceftriaxone, an 
antibiotic that induces both EAAT2 and NRF2 simultaneously, did not 
show efficacy in an ALS clinical trial [223]. 
NRF2 also participates in calcium homeostasis. Primary neuronal 
cultures from NRF2-null mice display decreased levels of calcium buff-
ering proteins, such as CALBINDIN D28K [224], and are prone to raise 
intracellular calcium levels. This finding correlates with the reduced 
level of CALBINDIN D28K described in MNs of ALS patients and suggests 
that NRF2 activation could reinforce calcium buffer capacity of MNs 
and, therefore, prevent the deleterious activation of some 
calcium-activated enzymes like calpain protease [225]. NRF2 activation 
by dimethyl fumarate has demonstrated calcium homeostatic abilities in 
human astrocytes harbouring SOD1 mutation through a mechanism 
involving its downstream target Glutathione peroxidase 8 (GPX8) [226]. 
GPX8 is enriched in mitochondria-associated membranes at the endo-
plasmic reticulum and activates the sarco-endoplasmic reticulum 
ATPase 2b (SERCA2b). Mechanistically, GPX8 expression reduced the 
level of calcium in endoplasmic reticulum and in resting cytosolic cal-
cium levels [226,227]. 
7. NRF2 as a druggable target to combat ALS hallmarks 
The incomplete understanding of pathophysiological mechanisms in 
ALS, limitations of disease models, the genetic and phenotypic hetero-
geneity of the disease and the limitations in clinical trial design have all 
undoubtedly contributed to the lack of predictive early biomarkers and 
adequate neuroprotective treatments for ALS [228]. Since 1996, riluzole 
is the only marketed therapy for ALS patients. Riluzole delays the onset 
of ventilator-dependence or tracheostomy in some patients and in-
creases survival by only approximately 3 months [229]. As discussed 
above, many pathomechanisms contribute to MN injury [230] and 
riluzole, as an anti-glutamate agent, only ameliorates one of these 
mechanisms, i.e. excitotoxicity, and it is therefore not surprising that the 
effect of this drug is modest. This emphasizes the need for a crucial 
reassessment of methods used in ALS drug development at the level of 
molecular target identification and clinical trial design and 
implementation. 
Therapies targeting individual pathways have universally failed to 
achieve positive effects in ALS clinical trials for more than 50 years. In 
fact, the promising results obtained in preclinical models submitted to 
antioxidant therapy have been poorly translated into clinical advances 
for ALS patients. Placebo-controlled randomized clinical trials aimed to 
address efficacy of vitamin E, α-tocopherol, β-carotene, lutein and 
lycopeno did not appear to affect survival and motor function in ALS 
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[231]. All these studies retrieved contradictory, inconclusive or scarcely 
statistically significant results. The principal disadvantages seem to be 
related with the higher antioxidant needed dosages and poor bioavail-
ability. In this review, we discuss an exciting and innovative class of 
drugs that activate the transcription factor NRF2 and might provide 
protection against many if not all hallmarks of ALS pathology (Fig. 5A). 
7.1. Therapeutic effects of NRF2 activation in preclinical models of ALS 
Genetic activation of NRF2 in astrocytes results in beneficial neu-
roprotective effects. The toxicity of astrocytes expressing ALS-linked 
mutant SOD1 to co-cultured MNs was reversed by NRF2 over- 
expression. NRF2 overexpression in astrocytes significantly delayed 
onset and extended survival in two ALS-mouse models [72,232]. 
The physiological activation of NRF2 by endogenous antioxidant 
molecules has been analyzed in ALS models. Nitro-fatty acids (NO2-FA) 
are electrophilic signaling mediators released during inflammation, 
which can activate NRF2-responsive genes in astrocytes and prevent the 
death of MNs in cell culture [233]. ANG is a secretory vertebrate RNase 
that enters neuronal cells and cleaves a subset of tRNAs, leading to the 
inhibition of translation initiation and the assembly of stress granules. 
Mutations in the ANG gene are a cause of ALS [234] and administration 
of human ANG to ALS mouse models extends lifespan and improves 
motor function [235]. Of note, ANG activates NRF2-target genes in 
murine astrocytes, including Nqo1, Gclm, and Gstα4, resulting in pro-
tection against oxidative stress [236]. Urate (2,6,8-trioxy-purine), the 
end product of dietary purines, has been proposed as prognostic factor 
for survival in ALS since its levels are reduced in the serum of ALS pa-
tients [237]. Interestingly, urate is an important endogenous antioxidant 
in humans [238] that activates NRF2 in an AKT/GSK3β-dependent 
manner [239]. Thus, in mutant SOD1-overexpressed NSC34 motor 
neuron cells and in Drosophila models of ALS, urate exerted neuro-
protection against oxidative damage by increasing GSH production 
through the activation of the NRF2/GCLC axis [239]. 
NRF2 activation has been driven by small molecule electrophiles that 
react with KEAP1 and previous studies supported the use of two syn-
thetic triterpenoid compounds (CDDO and CDDO-EA). With treatment 
at the pre-symptomatic stage, both compounds significantly attenuated 
weight loss, enhanced motor performance, and extended the survival of 
the SOD1G93A mice. When administered at the symptomatic stage, NRF2 
activation was neuroprotective and slowed disease progression [240]. 
The small molecule S [+]-apomorphine, a receptor-inactive enantiomer 
of the clinically approved dopamine-receptor agonist (R [-]-apomor-
phine), was identified as an NRF2 activator emerging from library 
screening. Notably, mice treated with S [+]-apomorphine showed in-
duction of NRF2 controlled genes in the brain, and significant attenua-
tion of motor dysfunction in SOD1G93A mice. S [+]-apomorphine also 
reduced pathological ROS levels and improved survival following 
oxidant challenge to fibroblasts from ALS patients. This molecule 
emerges as a promising candidate for evaluation as a potential 
neuroprotective agent in ALS patients in the clinic [241]. The same ALS 
mouse model has been used to investigate the efficacy of the powerful 
free-radical scavenging agent TBN (2-[[(1,1-dimethylethyl) 
oxidoimino]-methyl]-3,5,6-trimethylpyrazine) which activates the 
NRF2/HO1 axis. When administered after the onset of motor dysfunc-
tion, TBN improved motor performance, reduced spinal motor neuron 
loss and the associated glial response, decreased denervation at the 
neuromuscular junction and decreased the expression of human SOD1 
[242]. NRF2 activation resulting from SIRT6 overexpression abrogates 
the MN damage exerted by co-cultured astrocytes isolated from mutant 
SOD1-overexpressing mice [243]. The new compound WN1316 
(2-[mesityl (methyl)amino]-N-[4-(pyridin-2-yl)-1H-imidazole-2-yl] 
acetamide trihydrochloride) boosts the NRF2 transcriptional signature 
in SH-SY5Y neuronal cells. Oral administration of WN1316 in SOD1H46R 
and SOD1G93A mice improved motor function and survival. Immuno-
histochemical analysis revealed less oxidative DNA damage and reduced 
pro-inflammatory markers as well as repression of both microgliosis and 
astrocytosis compared to vehicle treated mice [244]. Recently, the 
antioxidant γ-oryzanol exhibited neuroprotection in MNs of flies 
expressing SOD1G85R, as demonstrated by prolonged survival, 
improvement of motor deficits, reduced oxidative damage and regulated 
redox homeostasis when compared with controls. Remarkably, γ-ory-
zanol significantly increased the pool of reduced GSH by the activation 
of the NRF2/GCLC axis [245]. CPN-9 (N-(4-(2-pyridyl) (1,3-thia-
zol-2-yl))-2-(2,4,6-trimethylphenoxy) acetamide) upregulates NRF2 and 
the expression of its target genes such as HMOX1, NQO1 and GCLM. 
Systemic administration of CPN-9 to SOD1H46R mice, administered after 
disease onset, resulted in improved motor function, and delayed disease 
progression [246]. 
Fingolimod phosphate (FTY720), the first approved oral therapy for 
multiple sclerosis was administered to SOD1G93A mice, starting from the 
onset of motor symptoms to the end stage of the disease. The drug was 
able to improve the neurological phenotype and to extend the survival. 
The beneficial effect of fingolimod administration was associated with a 
significant modulation of neuroinflammatory and protective genes 
including Cd11b, Foxp3, iNOS, Il1β, Il10, Arg1, and Bdnf [247]. An 
additional study demonstrated that fingomilod phosphate induces nu-
clear accumulation of NRF2, enhancing the transcription of its target 
genes [248]. 
The free radical scavenger edaravone (MCI-186, 3-methyl-1-phenyl- 
2-pyrazolin-5-one, Mitsubishi Tanabe Pharma Corporation, Tokyo, 
Japan) was reported as a therapeutic drug for ALS, modestly slowing the 
progression of disability measured by the ALS functional rating scale 
(ALSS-FRS-R) and motor neuron degeneration in SOD1 mice and rats 
[249,250]. The NRF2 signaling pathway was activated after edaravone 
treatment in cultured neurons, and its neuroprotective effect was abol-
ished after NRF2 knockdown [251]. In vivo imaging showed that eda-
varone reduced the levels of oxidative stress in the spinal cord and 
skeletal muscle of in SODG93A mice [252]. 
Fig. 5. NRF2 as a molecular target to combat pathophysiological hallmarks of ALS. A, development of NRF2 activators for cytoprotection of ALS-damaged cells. B, 
compounds that have proved cytoprotection through NRF2 activation in preclinical models and those which are currently under development or in clinical trials. 
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7.2. Clinical trials and therapies aimed at reinforcing NRF2 activity 
All the pre-clinical data described above pave the way to analyze 
whether NRF2 activation might have beneficial disease-modifying ef-
fects in human ALS clinical trials. Several ALS clinical trials have 
explored the therapeutic potential of edavarone. However, this drug 
only produced a limited decline of the ALSFRS-R score compared with 
placebo in a highly selected group of ALS patients followed over a short 
6-month time period [9,253] (NCT01492686 and NCT00330681). The 
CSF content of 3NT, a marker for oxidative stress, was markedly reduced 
in edavarone treated patients to almost undetectable levels at the end of 
the six-month treatment period, although this biomarker was not 
included in the final pivotal trial [254]. In addition, the route of 
administration, intravenous infusion for 10 days each month, is 
burdensome for patients. Edaravone has been approved for ALS treat-
ment in the US and Japan, but not in Europe. The possibility of devel-
oping an oral preparation of edaravone is being explored. 
Repurposing the NRF2 activators, fingolimod phosphate and 
dimethyl fumarate (DMF), should be a feasible strategy since both are 
already approved by the Food and Drug Administration and the Euro-
pean Medicines Agency for the treatment of multiple sclerosis, with 
neuroprotective efficacy in animal models of ALS [170,171,247]. The 
objective of the figolimod (Gilenya TM, Novartis AG) Phase IIA, ran-
domized, controlled trial was to test the short-term safety, tolerability, 
and target engagement in ALS. No serious adverse events occurred. In 
line with NRF2 anti-inflammatory properties, circulating lymphocytes 
decreased significantly and several immune-related genes were down-
regulated in the fingolimod arm compared with placebo. However, there 
was no observable benefit of fingolimod on the ALSFRS-R or respiratory 
function in this Phase 2A trial [255] (NCT01786174). Since October 
2017, the TEALS Study (ACTRN12618000534280) has been assessing 
the efficacy of DMF on disease progression measured by the ALS-FRS-R 
in SALS patients. The secondary aim of this study is to assess survival, 
MN dysfunction, respiratory dysfunction, quality of life as well as safety 
and tolerability. The authors of this study anticipate that the results will 
be available during 2021 [256]. S [+] apomorphine, which is a potent 
dual activator of the NRF2 and HSF1 (heat shock factor 1) pathways, 
with excellent penetration into the CNS across the blood brain barrier, is 
progressing towards human trials in 2021, and will incorporate imaging 
and biochemical biomarkers of target engagement and therapeutic 
efficacy. 
Pharmacological activation of NRF2 holds promise for the treatment 
of other neurodegenerative diseases such as Friedreich ataxia (FRDA). 
As in the case of ALS, FRDA is a neuromuscular disorders in which NRF2 
is downregulated [257–259], and oxidative and inflammatory stress are 
important drivers of pathology. There are no currently approved ther-
apies for the treatment of FRDA [260] and the role of omaveloxolone, a 
potent NRF2 activator with a pentacyclic triterpenoid structure, is under 
clinical development by Reata Pharmaceuticals. The safety and efficacy 
of omaveloxolone has been tested in a registrational phase II clinical 
trial for patients with FRDA (MOXIe trial). MOXIe trial provided evi-
dence that omaveloxolone significantly improved neurological function 
compared to placebo and was generally safe and well tolerated [261] 
(NCT02255435). The lessons learned from this trial could be certainly 
translated into novel therapies for ALS, supporting NRF2 as a thera-
peutic agent (Fig. 5B). 
8. Perspectives 
The pathophysiological hallmarks of ALS include loss of homeostatic 
responses such as RNA metabolism, redox control, inflammation, pro-
teostasis and excitotoxicity. The multilayered aspects of ALS heteroge-
neity could be targeted with one single hit at the transcription factor 
NRF2 to orchestrate a neuroprotective response. Based on preclinical 
studies, biopharmaceutical companies are determining whether NRF2 
activation could be a feasible strategy for ALS patients. Although NRF2 
activation is very promising, we are aware that some questions are still 
challenging. Pharmacodynamic assessment (i.e. monitoring target 
engagement and off-target effects) and drug selectivity of NRF2 acti-
vators could be improved beyond the state of the art. Undoubtedly, 
active research conducted on improved preclinical ALS models and the 
data obtained from the ongoing clinical trials will offer answers to the 
currently open questions. 
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